NCT03907878View on ClinicalTrials.gov

A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines

PHASE3CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

April 13, 2019

Primary Completion Date

January 26, 2022

Study Completion Date

January 26, 2022

Conditions
Chronic Spontaneous Urticaria
Interventions
BIOLOGICAL

Ligelizumab

Liquid in vial

Trial Locations (11)

272-0033

Novartis Investigative Site, Ichikawa

080 0013

Novartis Investigative Site, Obihiro

650-0017

Novartis Investigative Site, Kobe

663-8186

Novartis Investigative Site, Nishinomiya

221-0825

Novartis Investigative Site, Yokohama

222-0033

Novartis Investigative Site, Yokohama

572-0838

Novartis Investigative Site, Neyagawa

593-8324

Novartis Investigative Site, Sakai

173-8610

Novartis Investigative Site, Itabashi-ku

194-0013

Novartis Investigative Site, Machida

734-8551

Novartis Investigative Site, Hiroshima

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY